Sanofi's mRNA Vaccine for Coronavirus to Enter Clinical Stage
Sanofi’s SNY global vaccines business unit Sanofi Pasteur and Translate Bio, Inc. TBIO announced promising pre-clinical data on their coronavirus vaccine candidate MRT5500. Pre-clinical data demonstrated a favorable immune response profile against SARS-CoV-2 in mice and non-human primates.
The preclinical data showed that two doses of MRT5500 induced neutralizing antibody levels significantly higher than those observed in COVID-19 patients.
The companies evaluated four dose levels — 0.2, 1, 5 and 10 µg per dose — of MRT5500 in mice and three dose levels — 15, 45 and 135 µg per dose — in non-human primates (NHPs). The vaccine has been developed as a two-administration vaccination schedule, three weeks apart.
Pre-clinical findings from the mice study showed that the candidate induced higher levels of binding antibodies and neutralizing antibodies specific to the SARS-CoV-2 spike protein with higher level of dose. First administration of MRT5500 achieved 100% seroconversion at all dose levels and a further increase in titers was observed following a second administration in the mice.
MRT5500 induced significantly higher levels of neutralizing antibody titers in NHPs compared to human convalescent sera by day 35. The candidate exhibited a Th1-biased T cell response against SARS-CoV-2 in both mice and NHPs.
These outcomes supported selection of the candidate for clinical development. A phase I/II study is planned for late 2020 to evaluate MRT550 in humans. Please note that Sanofi and Translate Bio have a collaboration agreement to develop novel mRNA vaccines, aimed at broadly addressing all current and future infectious diseases including COVID-19.
Shares of Sanofi have dipped 0.5% so far this year compared with the industry’s decrease of 0.9%.
Apart from MRT5500, Sanofi is developing another COVID-19 vaccine candidate in collaboration with Glaxo GSK. Sanofi’s recombinant protein-based technology is being combined with Glaxo’s pandemic adjuvant technology to develop an adjuvanted COVID-19 vaccine. In September, a phase I/II study was initiated to evaluate their adjuvanted vaccine. Initial results from the study are expected in early December 2020. If phase I/II study data is favorable, the companies are likely to begin a pivotal phase III study before the end of this year.
Meanwhile, we note that there are other players in the coronavirus vaccine field with a few already in late-stage development. Leading coronavirus vaccine developers include Moderna MRNA, Pfizer/BioNTech, AstraZeneca/Oxford University and J&J. Currently, Pfizer/BioNTech’s mRNA-based coronavirus vaccine candidate is leading the race with initial data from a late-stage study expected by the end of this month. Positive outcomes will likely support an emergency use authorization from the FDA.
Sanofi currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Sanofi (SNY): Free Stock Analysis Report
Moderna, Inc. (MRNA): Free Stock Analysis Report
GlaxoSmithKline plc (GSK): Free Stock Analysis Report
Translate Bio, Inc. (TBIO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.